Oncology News

Nivolumab plus chemotherapy continued to confer clinically meaningful improvement in OS and PFS as first-line therapy for advanced gastric and esophageal cancers, according to a study presented at Gastrointestinal Cancers Symposium.

Patients with IgG4-related disease are at a higher risk for cancer — particularly pancreatic and lymphoma — compared with the general population, according to a meta-analysis published in Arthritis Research & Therapy.

In a Healio video exclusive, John Inadomi, MD, president of the American Gastroenterological Association, outlined the Biden administration’s new guidance requiring private insurers to cover the cost of follow-up colonoscopy.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma, according to a phase 3 study conducted in Asia.

The FDA granted fast track designation to CYNK-101, a natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.

Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced, unresectable hepatocellular carcinoma, according to research scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.

The addition of durvalumab to gemcitabine and cisplatin significantly extended OS among patients with advanced biliary tract cancer, according to results of a phase 3 study scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.

The ACP has released its first-ever guidelines for diagnosing, managing and preventing recurrence of acute left-sided colonic diverticulitis.

Camrelizumab combined with apatinib may potentially be used as a second-line treatment for advanced esophageal squamous cell carcinoma, according to phase 2 results published in The Lancet Gastroenterology & Hepatology.

The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.